Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE

Janssen’s guselkumab and golimumab combination fares well in Phase 2a ulcerative colitis study

By Brian Buntz | October 10, 2022

Johnson & Johnson Janssen pharmaceutical business in the Pharma 50Johnson & Johnson’s Janssen subsidiary has released positive data from an ongoing analysis of the Phase 2a VEGA clinical study of guselkumab and golimumab. The trial focused on adults with moderately to severely active ulcerative colitis (UC).

The study tested the efficacy of 12 weeks of combination induction therapy with the interleukin-23 subunit p19 inhibitor guselkumab and the TNFα inhibitor golimumab. After that period, the participants received guselkumab alone for maintenance.

At week 38, recipients of the guselkumab and golimumab combination therapy had a clinical remission rate of 47.9%. For the sake of comparison, the remission rate for guselkumab alone was 31.0%, while the rate for golimumab alone was 20.8%.

The study defined clinical response using the Mayo score, which is the sum of four subscores related to stool frequency, rectal bleeding, physician’s global assessment and endoscopy findings.

Groups in all three arms had similar adverse event rates.

In the U.S., guselkumab is approved for moderate to severe plaque psoriasis and active psoriatic arthritis.

In 2020, guselkumab became the first IL-23 inhibitor to win an FDA indication for active psoriatic arthritis in 2020.

Using guselkumab alone and in combination with golimumab remains investigational for ulcerative colitis.

In the combination arm, recipients received the first dose of guselkumab as an IV infusion. The second dose of the drug was administered subcutaneously. The first and second doses of golimumab was provided as a subcutaneous injection and placebo to maintain blinding.

Janssen will present the new data at the United European Gastroenterology Week 2022 congress.

The company notes that the VEGA trial is the first randomized controlled study to test the combination therapy with an interleukin (IL)-23p19 subunit antagonist and TNFα antagonist in ulcerative colitis. The VEGA study enrolled a total of 214 participants.

Simponi (golimumab) first won FDA approval for rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis in 2009.


Filed Under: Gastroenterology
Tagged With: golimumab, guselkumab
 

About The Author

Brian Buntz

As the pharma and biotech editor at WTWH Media, Brian has almost two decades of experience in B2B media, with a focus on healthcare and technology. While he has long maintained a keen interest in AI, more recently Brian has made making data analysis a central focus, and is exploring tools ranging from NLP and clustering to predictive analytics.

Throughout his 18-year tenure, Brian has covered an array of life science topics, including clinical trials, medical devices, and drug discovery and development. Prior to WTWH, he held the title of content director at Informa, where he focused on topics such as connected devices, cybersecurity, AI and Industry 4.0. A dedicated decade at UBM saw Brian providing in-depth coverage of the medical device sector. Engage with Brian on LinkedIn or drop him an email at bbuntz@wtwhmedia.com.

Related Articles Read More >

Austrian researchers find IgA-tagged vesicles turn gut’s own antibodies against it, worsening ulcerative colitis
One of C. difficile’s metabolic powers might be turning a toxin into a fuel
Eli Lilly in the Drug Discovery & Development Pharma 50
Lilly’s FDA approval for Omvoh close up: Nearly 90% of one-year responders maintained remission through two years
Lumen Bioscience
How an engineered algae-based biologic aims to break the annual $5B cycle of c. diff reinfection
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE